On 7 July 2021, the biopharmaceutical industry welcomed the opportunity to join the 
International Coalition of Medicines Regulatory Authorities (ICMRA) in a workshop focused on expanding manufacturing capacity for COVID-19 medicines and vaccines. This workshop provided a platform to collectively explore the range of activities associated with post-approval site transfers and review the regulatory flexibilities implemented by ICMRA members during the pandemic. Solutions discussed reflected the spirit of collaboration, co-operation and co-creation which has featured so strongly between all partners seeking to respond to the pandemic and the global public health needs.
See the full statement here
